文献速递肿瘤 PET/CT核素与放射性配体治疗

中期[18F]FDG PET/CT可预测转移性黑色素瘤抗PD-1治疗反应

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-12-18

按PERCIMT标准,代谢获益组无进展生存期显著长于无获益组(p=0.045);按EORTC标准则无显著差异(p=0.088)。

要点

  • PERCIMT标准评估的中期PET/CT代谢获益与PFS显著相关(p=0.045)。
  • EORTC标准下代谢获益与无获益组PFS无显著差异(p=0.088)。
  • 放射性irAEs出现(11例)未伴随显著生存获益。

核心结论

  • 按PERCIMT标准评估的中期[18F]FDG PET/CT代谢反应与转移性黑色素瘤抗PD-1治疗的PFS显著相关。

研究设计与样本

  • 在治疗前(基线)和初始两周期PD-1阻断后(中期)行[18F]FDG PET/CT,17例在四周期治疗后还行第三次PET/CT。
  • 采用EORTC 1999标准和PERCIMT标准评估代谢反应,分为CMR、PMR、SMD和PMD,并将SMD、PMR、CMR归为代谢获益(MB),PMD归为无代谢获益(no-MB)。
  • PFS从中期PET/CT日期起算至疾病进展或任何原因死亡。

主要发现

  • 自中期PET/CT起中位随访24.2个月(19.3-41.7个月)。
  • 按EORTC标准,14例为MB(1例CMR、6例PMR、7例SMD),11例为no-MB(PMD)。
  • 按PERCIMT标准,19例为MB(1例CMR、6例PMR、12例SMD),6例为no-MB(PMD)。
  • 按EORTC标准,MB与no-MB组PFS无显著差异(p=0.088);按PERCIMT标准,MB组PFS显著长于no-MB组(p=0.045)。
  • 11例出现提示放射性irAEs的[18F]FDG摄取模式,但与显著生存获益无关。

关键数值与推荐

  • EORTC 1999标准:MB 14例(1 CMR、6 PMR、7 SMD),no-MB 11例(PMD),PFS差异p=0.088。
  • PERCIMT标准:MB 19例(1 CMR、6 PMR、12 SMD),no-MB 6例(PMD),PFS差异p=0.045。

临床怎么用

  • 对转移性黑色素瘤抗PD-1治疗患者,可考虑在初始两周期后行[18F]FDG PET/CT,并采用PERCIMT标准评估代谢反应以早期分层。
  • EORTC标准在此场景下未显示显著PFS区分能力,解读时应结合所用标准。

局限性

  • 仅17例完成第三次PET/CT,中期与后期反应一致性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [18F]FDG PET/CT, performed at baseline and early during the course of anti-PD-1 treatment. METHODS: Twenty-five patients with stage IV melanoma, scheduled for treatment with PD-1 inhibitors, were enrolled in the study (pembrolizumab, n = 8 patients; nivolumab, n = 4 patients; nivolumab/ipilimumab, 13 patients). [18F]FDG PET/CT was performed before the start of treatment (baseline PET/CT) and after the initial two cycles of PD-1 blockade administration (interim PET/CT). Seventeen patients underwent also a third PET/CT scan after administration of four cycles of treatment. Evaluation of patients' response by means of PET/CT was performed after application of the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria and the PET Response Evaluation Criteria for IMmunoTherapy (PERCIMT). Response to treatment was classified into 4 categories: complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD). Patients were further grouped into two groups: those demonstrating metabolic benefit (MB), including patients with SMD, PMR, and CMR, and those demonstrating no MB (no-MB), including patients with PMD. Moreover, patterns of [18F]FDG uptake suggestive of radiologic immune-related adverse events (irAEs) were documented. Progression-free survival (PFS) was measured from the date of interim PET/CT until disease progression or death from any cause. RESULTS: Median follow-up from interim PET/CT was 24.2 months (19.3-41.7 months). According to the EORTC criteria, 14 patients showed MB (1 CMR, 6 PMR, and 7 SMD), while 11 patients showed no-MB (PMD). Respectively, the application of the PERCIMT criteria revealed that 19 patients had MB (1 CMR, 6 PMR, and 12 SMD), and 6 of them had no-MB (PMD). With regard to PFS, no significant difference was observed between patients with MB and no-MB on interim PET/CT according to the EORTC criteria (p = 0.088). In contrary, according to the PERCIMT criteria, patients demonstrating MB had a significantly longer PFS than those showing no-MB (p = 0.045). The emergence of radiologic irAEs (n = 11 patients) was not associated with a significant survival benefit. Regarding the sub-cohort undergoing also a third PET/CT, 14/17 patients (82%) showed concordant responses and 3/17 (18%) had a mismatch of response assessment between interim and late PET/CT. CONCLUSION: PET/CT-based response of metastatic melanoma to PD-1 blockade after application of the recently proposed PERCIMT criteria is significantly correlated with PFS. This highlights the potential ability of [18F]FDG PET/CT for early stratification of response to anti-PD-1 agents, a finding with possible significant clinical and financial implications. Further studies including larger numbers of patients are necessary to validate these results.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sachpekidis C, Kopp-Schneider A, Pan L, et al. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 33336264. doi:10.1007/s00259-020-05137-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。